Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
about
Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Liquid biopsy genotyping in lung cancer: ready for clinical utility?Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIsTotal DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs.Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.Current and Emerging Applications of Droplet Digital PCR in Oncology.Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing.Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC.Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer.Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report.Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patientsDetection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysisThe resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer.Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.Circulating DNA in EGFR-mutated lung cancer.Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction.Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer.An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients.A comparison of ARMS-Plus and droplet digital PCR for detecting EGFR activating mutations in plasma.An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns.Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer.Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules.A Multicenter Study to Assess Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting
P2860
Q26741814-26C10A23-CD95-43A1-AF64-A0A9FE3A4D42Q33567037-8CAB2D2C-A9AB-4380-A7C7-F99A146E940EQ33798826-BEBA9D30-AC3C-42A8-A9DE-8296C4D61F02Q36233903-0C892AC8-6E9F-47C7-927D-66F9FE8F0C27Q36319739-E6A0E052-2BBE-4A7F-A50F-1FDA1C9D879BQ37701499-551A8A11-85AE-43A9-BF5E-EE89F9C88CB5Q37706578-3E7201FF-AF9C-4E43-9771-1D5081BA7E43Q37709234-6A9A4438-0C55-41F2-81E3-5B26CFC0A0B9Q38374623-14326F37-E8C9-430F-BA28-04FE493173C6Q38651333-9F090EEE-B04F-4546-8096-6CC92C0678E2Q38664177-F7514898-9E1D-43ED-951A-8887042B61F9Q38824891-23705F90-D41E-4C0E-B564-ADC48790C1EAQ39002233-8678BD7F-BEE2-43A7-960A-BB3130211399Q40489387-F73B32E5-1AF9-44CE-9FA2-04E6A1945BE5Q41260159-C404FBCB-5422-464F-A392-95F760C3BDF4Q41862850-C60B74AB-74AA-41EA-9458-6C2A3313AD19Q42362771-F3D95E37-D710-49CD-8339-307EFB5F3751Q42371507-60978E02-32E1-4581-8A0A-78C6F0A1E2F7Q42378535-19474E71-FDBB-40A8-A96C-BFEE892E9A57Q42835050-68F573BF-F4F9-469F-B9DA-552364C5D365Q45886897-1A3D75DC-8E11-480C-83B0-2EA17066F183Q46917029-7CB1F646-3F58-4B95-BF3B-9A75FC17DFACQ47109269-049EC762-9283-47B9-B627-EFCD520CF255Q47162466-1A0FA8ED-1ED1-471E-972E-B674194190C7Q48179589-DDB649AF-F864-4D9F-95AF-C14F994A4917Q48499401-9FBB2412-9E9C-4AD2-AEB3-27F9A25CFA4FQ48505939-B6AA3F9A-7C88-4E62-8634-639A33D8A39EQ49667322-84CDEB21-352D-423B-8D62-09D02F4D3C6AQ53721511-E1A71CBE-E2AB-4D4B-8D28-A69984440DCDQ55282794-906C969B-B28A-49CA-8A53-FB882A19E901Q55422540-CE396676-841D-40F5-BB95-277F5B0AC18DQ58700168-A279E6E4-1FA5-4308-AFFA-C579268772BC
P2860
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Longitudinal monitoring of EGF ...... Cancer Consortium (KLCC-12-02)
@en
type
label
Longitudinal monitoring of EGF ...... Cancer Consortium (KLCC-12-02)
@en
prefLabel
Longitudinal monitoring of EGF ...... Cancer Consortium (KLCC-12-02)
@en
P2093
P2860
P356
P1433
P1476
Longitudinal monitoring of EGF ...... Cancer Consortium (KLCC-12-02)
@en
P2093
Dong-Wan Kim
Eun Kyung Cho
Ho Yun Lee
Hye Ryun Kim
Ji Yun Lee
Jin Seok Ahn
Jong-Mu Sun
Keunchil Park
P2860
P304
P356
10.18632/ONCOTARGET.6874
P407
P577
2016-01-09T00:00:00Z